Vivesto (BATS-CHIXE:VIVES) - Stock Price, News & Analysis

VIVES Stock Overview

Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden.

VIVES fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Earnings have declined by 8.5% per year over past 5 years

Makes less than USD$1m in revenue (SEK7M)

+ 1 more risk

Vivesto AB Competitors

Theracryf

AIM:TCF

UK£3.0m

Arecor Therapeutics

AIM:AREC

UK£34.4m

ProBiotix Health

OFEX:PBX

UK£4.9m

Verici Dx

AIM:VRCI

UK£16.4m

Price History & Performance

Summary of all time highs, changes and price drops for Vivesto
Historical stock prices
Current Share Price	SEK 0.28
52 Week High	SEK 0
52 Week Low	SEK 0
Beta	0.63
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	VIVES	GB Biotechs	GB Market
7D	n/a	-0.1%	0.3%
1Y	n/a	-18.7%	11.6%

Return vs Industry: Insufficient data to determine how VIVES performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how VIVES performed against the UK Market.

Price Volatility

Is VIVES's price volatile compared to industry and market?
VIVES volatility
VIVES Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.7%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: VIVES has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine VIVES's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1988	6	Erik Kinnman	www.vivesto.com

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.

Vivesto AB Fundamentals Summary

How do Vivesto's earnings and revenue compare to its market cap?
VIVES fundamental statistics
Market cap	SEK 145.27m
Earnings (TTM)	-SEK 116.77m
Revenue (TTM)	SEK 6.61m

22.0x

P/S Ratio

-1.2x

P/E Ratio

Is VIVES overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIVES income statement (TTM)
Revenue	SEK 6.61m
Cost of Revenue	SEK 0
Gross Profit	SEK 6.61m
Other Expenses	SEK 123.38m
Earnings	-SEK 116.77m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 22, 2024

Earnings per share (EPS)	-0.22
Gross Margin	100.00%
Net Profit Margin	-1,766.05%
Debt/Equity Ratio	0%

How did VIVES perform over the long term?

See historical performance and comparison